Bifidobacterium breve Bif195 Protects Against Small-intesti…

A CCEPTED MANUSCRIPT

Table 1. Subject baseline characteristics and trial compliance of the analysis population.

Bif195

Placebo

N

35

31

Age (years)

30.5 ± 6.8

31.2 ± 6.4

Gender (m/f)

16/19

14/17

Ethnicity (non-caucasians)

2

0

Height (cm)

172.2 ± 12.1 173.4 ± 10.2

Weight (kg)

73.5 ± 12.5

72.0 ± 11.4

BMI (kg/m^2)

24.6 ± 2.1

23.8 ± 2.2

Blood pressure, Systolic (mm hg)

124.1 ± 7.8

121.6 ± 10.2

Blood pressure, Diastolic (mm hg)

78.7 ± 6.9

77.1 ± 7.6

alcohol consumption (“drinks” per week)

5.1 ± 3.2

5.5 ± 3.7

MANUSCRIPT 98.7 ± 2.4 99.1 ± 1.9 98.6 ± 2.4 99.0 ± 1.9

Compliance of ASA intake (%, 100% = product subj. should have taken during trial)

Compliance of trial product (%, 100% = product subj. should have taken during trial)

Body-mass index, BMI, is the weight in kilograms divided by the square of height in meters. Numbers are given as Mean ± SD.

Powered by